| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-16 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Announces Participation at Upcoming Investor Conferences |
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference Forum: Fireside ChatDate: Tuesday, May 20, 2025Time: 10:00 a.m. |
globenewswire.com |
2025-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript |
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker - President & Chief Executive Officer Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Jennifer Kim - Cantor Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Nick Quartapella - Baird Deb Chatterjee - Jones Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citigroup Operator Good morning. My name is Towanda and I will be your conference operator today. |
seekingalpha.com |
2025-05-07 18:49:21 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-07 14:36:40 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates |
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago. |
zacks.com |
2025-05-07 13:25:47 |
Czytaj oryginał (ang.) |
| EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments |
– Enrollment continues to exceed expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials expected in 2026 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2025, and highlighted recent corporate developments. |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 |
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and highlight recent corporate developments. |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-16 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference |
WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Conference on Friday, April 4, 2025 at 10:00 a.m. ET. |
globenewswire.com |
2025-03-27 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-17 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript |
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Yigal Nochomovitz - Citigroup Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Jennifer Kim - Cantor Fitzgerald Graig Suvannavejh - Mizuho Securities Colleen Kusy - Baird Debanjana Chatterjee - JonesTrading Gregory Harrison - Scotiabank Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good morning. |
seekingalpha.com |
2025-03-05 16:51:33 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for EyePoint Pharmaceuticals (EYPT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-03-05 12:30:41 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates |
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2025-03-05 11:25:29 |
Czytaj oryginał (ang.) |
| EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments |
– Enrollment exceeding expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash and investments on December 31, 2024, providing cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – WATERTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2024, and highlighted recent corporate developments. |
globenewswire.com |
2025-03-05 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Announces Participation at Upcoming Investor Conferences |
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences: Leerink Partners Global Healthcare Conference Forum: Corporate PresentationDate: Tuesday, March 11, 2025Time: 4:20 p.m. |
globenewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 |
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference |
– Company presentation scheduled on Tuesday, March 4 th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME – WATERTOWN, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. |
globenewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-17 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival |
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoing Phase 3 studies suggest significant upside potential, though past mixed results and heavy competition raise risks. Recent fundraising and a new manufacturing facility indicate strong commitment, but the company's financial health and market skepticism remain concerns. |
seekingalpha.com |
2025-01-30 14:39:55 |
Czytaj oryginał (ang.) |
| EyePoint to Present at Guggenheim SMID Cap Biotech Conference |
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET. |
globenewswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-16 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D. |
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. |
globenewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-16 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration |
– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the LUCIA trial, the Company's second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). |
globenewswire.com |
2024-12-04 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity |
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety, and efficacy, and reduced treatment burden, positioning it as a potential long-term solution for retinal diseases. Despite a failed NPDR trial, positive DME data suggest potential for targeting more severe diabetic retinopathy, enhancing the investment thesis. |
seekingalpha.com |
2024-11-14 07:04:43 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? |
The mean of analysts' price targets for EyePoint Pharmaceuticals (EYPT) points to a 175.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-13 13:00:55 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates |
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2024-11-07 11:35:19 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences |
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: |
globenewswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares |
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritten public offering of 14,636,363 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,909,090 shares of common stock, at the public offering price of $11.00 per share. Gross proceeds to EyePoint in the offering, before underwriting discounts and estimated expenses of the offering, were approximately $161.0 million. |
globenewswire.com |
2024-10-31 18:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering |
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 12,727,273 shares of its common stock at a public offering price of $11.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $140.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock are being sold by EyePoint. The closing of the offering is expected to occur on or about October 31, 2024, subject to the satisfaction of customary closing conditions. In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,909,090 shares of EyePoint's common stock at the public offering price, less underwriting discounts and commissions. |
globenewswire.com |
2024-10-29 23:47:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? |
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-29 07:50:28 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock |
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares are being offered by EyePoint. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15 million of shares of EyePoint's common stock at the public offering price, less the underwriting discount. |
globenewswire.com |
2024-10-28 19:14:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema |
- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - |
globenewswire.com |
2024-10-28 09:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration |
– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU™, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). |
globenewswire.com |
2024-10-24 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2024-10-16 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors |
- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - - Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - |
globenewswire.com |
2024-09-04 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade) |
EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boosted EyePoint's stock, but concerns remain about efficacy, financial strength, competition, and patient/physician adoption. A recent NPDR study failure caused a significant stock drop, but upcoming Phase 3 Wet AMD and Phase 2 DME data could provide new catalysts for gains. |
seekingalpha.com |
2024-08-29 21:35:33 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences |
WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: |
globenewswire.com |
2024-08-27 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Aug. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2024-08-16 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference |
WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference: |
globenewswire.com |
2024-08-08 11:00:00 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates |
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.61 per share a year ago. |
zacks.com |
2024-08-07 13:16:56 |
Czytaj oryginał (ang.) |
| EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). |
globenewswire.com |
2024-07-16 11:00:00 |
Czytaj oryginał (ang.) |